Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: JACC Cardiovasc Imaging. 2008 Sep;1(5):624–634. doi: 10.1016/j.jcmg.2008.06.003

Figure 3. MR Signal Enhancement up to Eight Weeks Post Treatment with Targeted Fumagillin Nanoparticles With and Without Oral Atorvastatin.

Figure 3

TOP: MRI enhancement in untreated (▲), atorvastatin treated (●) and fumagillin treated animals (■) during 8 weeks of follow-up imaging. Untreated and statin treated animals showed a constant level of angiogenesis in the aortic wall. Animals treated with targeted fumagillin nanoparticles at weeks 0 and 4 (0 & 4 wks) showed decreased angiogenesis (*p<0.05) following each dose, which returned to baseline levels within 4 weeks. BOTTOM: Enhancement in rabbits receiving atorvastatin alone (▲) or in conjunction with one (■) or two (●) doses of targeted fumagillin nanoparticles. The combination of two fumagillin doses and statin produced a sustained decrease in angiogenesis (*p<0.05).